8-K: Annexon Reports Third Quarter 2024 Results and Provides Key Program Updates

Annexon announced its third quarter 2024 financial results, highlighted progress in its clinical programs, and provided key anticipated milestones.

Summary

• Annexon reported a net loss of $34.8 million, or $0.25 per share, for the third quarter of 2024, compared to a net loss of $32.5 million, or $0.43 per share, for the same period in 2023.
• The company's research and development expenses were $30.1 million for the quarter, up from $27.9 million in the prior year.
• General and administrative expenses increased to $9.3 million from $6.9 million year-over-year.
• As of September 30, 2024, Annexon had approximately $340 million in cash, cash equivalents, and short-term investments.
• The company anticipates this cash runway will fund operations into the second half of 2026.
• Topline real-world evidence (RWE) data for ANX005 in Guillain-Barré Syndrome (GBS) is expected by the end of 2024, with a Biologics License Application (BLA) submission targeted for the first half of 2025.
• The Phase 3 ARCHER II trial for ANX007 in Geographic Atrophy (GA) is ongoing, with topline data expected in the second half of 2026.
• Data from the proof-of-concept study for the oral C1s inhibitor ANX1502 in Cold Agglutinin Disease (CAD) is expected in the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong cash reserves, progress in clinical trials, and key milestones on track. However, the increased net loss and expenses temper the overall sentiment slightly.

Positives

• The company has a strong cash position of $340 million, providing a runway into the second half of 2026.
• Positive Phase 3 data for ANX005 showed statistically significant effects on GBS.
• ANX007 has demonstrated significant vision protection in GA trials.
• The company is advancing a first-in-kind oral C1s inhibitor, ANX1502.
• Annexon has strengthened its leadership team in key areas.
• The company is progressing towards a BLA submission for ANX005 in GBS.

Negatives

• The company reported a net loss of $34.8 million for the quarter, an increase from $32.5 million in the same quarter of the previous year.
• Research and development expenses increased to $30.1 million from $27.9 million year-over-year.
• General and administrative expenses also increased to $9.3 million from $6.9 million year-over-year.

Risks

• The company is subject to risks and uncertainties related to clinical trials, regulatory approvals, and commercialization of its product candidates.
• There are risks associated with the company's reliance on third-party suppliers and manufacturers.
• The company has a history of net operating losses and may require additional capital in the future.
• There are risks related to the ongoing off-treatment follow-up portion of the ARCHER trial and final results from the ARCHER trial.
• The company faces risks related to maintaining intellectual property rights for its product candidates.

Future Outlook

The company anticipates a strong finish to 2024 and a significant start to 2025, with key data readouts and regulatory submissions expected. They also expect their current cash position to fund operations into the second half of 2026.

Management Comments

• The RWE data for our ANX005 GBS program expected by year end 2024 will be an important part of our first BLA submission as a company and a significant step toward providing GBS patients with a targeted and approved therapy.
• ARCHER II, our Phase 3 trial in GA, is actively enrolling and designed to provide the first significant data for protection of vision in a pivotal GA trial.
• We're anticipating data from our first-in-kind oral C1s program, ANX1502, with an improved tablet formulation in patients with CAD in the first quarter of 2025.
• Our portfolio of programs has provided consistent support for our approach to target C1q, a key upstream driver of neuroinflammatory diseases of the body, brain and eye, and we're encouraged by the outlook for our programs.
• With a strong balance sheet and runway into the second half of 2026, we are laser-focused to deliver on our near-term goals and achieve our mission of helping millions of patients live their best lives.

Industry Context

This announcement highlights Annexon's progress in developing novel therapies for neuroinflammatory diseases, a competitive and rapidly evolving field. The company's focus on C1q inhibition is a unique approach that could differentiate its treatments from existing therapies. The company is competing with other companies developing treatments for GBS, GA and CAD.

Comparison to Industry Standards

• Annexon's ANX005 for GBS is competing with standard treatments like IVIg and plasma exchange, with the goal of demonstrating superior outcomes.
• The Phase 3 ARCHER II trial for ANX007 in GA is competing with other companies developing treatments for GA, such as Apellis's Syfovre and Iveric Bio's Izervay, with the goal of demonstrating superior vision protection.
• The development of an oral C1s inhibitor, ANX1502, is a novel approach compared to existing treatments for autoimmune conditions, which often require infusions.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the company's financial performance and progress in clinical trials.
• Employees will be impacted by the company's growth and development.
• Patients with GBS, GA, and CAD stand to benefit from the company's potential new therapies.
• Suppliers and manufacturers will be impacted by the company's clinical and commercial activities.
• Creditors will be interested in the company's financial stability and cash runway.

Next Steps

• The company will complete the RWE comparability study for ANX005 in GBS by the end of 2024.
• Annexon plans to submit a BLA for ANX005 in the first half of 2025.
• The company will continue enrollment in the Phase 3 ARCHER II trial for ANX007 in GA.
• Annexon will release data from the proof-of-concept study for ANX1502 in CAD in the first quarter of 2025.
• The company will assess plans for an injection-controlled study, ARROW, to assess the prevention of 15-letter loss of BCVA.

Key Dates

Keywords

ANX005, ANX007, ANX1502, Guillain-Barré Syndrome, Geographic Atrophy, Cold Agglutinin Disease, C1q, C1s, Neuroinflammatory Diseases, Biologics License Application, Clinical Trials, RWE, Phase 3, Autoimmune, Ophthalmic